Hengray Pharmaceutical announced that it has entered into an agreement with Dr. Reddy's Laboratories of India (" Dr. Reddy's ") to license the development and commercialization rights of targeted drug pyrrotinib maleate tablets with independent intellectual property rights to Dr. Reddy's in India. Dr. Reddy's will make an initial payment of $3 million to Hengrui, up to a sales milestone of $152.5 million. Sales commissions amounting to a double-digit percentage of actual annual net sales will be paid to Hengrui